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Dengue Fever/Dengue Haemorrhagic Fever: Case Management
Suchitra NIMMANNITYA
Children 's Hospital, 420/8 Rajvithi Road, Bangkok 10,400 Thailand
Dengue infections caused by the four antigenically distinct dengue virus serotypes
(dengue virus 1, dengue virus 2, dengue virus 3, dengue virus 4) of the family Flavivindae,
are the most important arbovirus disease in man, both in terms of morbidity and mortality.
The infection is transmitted from man to man by Aedes mosquitoes. Since 1956, dengue
virus infection has resulted in more than 3 million hospital admissions and more than
50,000 deaths in Southeast Asia, Western Pacific countries, Cuba, the Caribbean Islands
and Venezuela1).
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Dengue virus infection may be asymptomatic or may lead to simple fever, dengue fever
(DF), or dengue haemorrhagic fever (DHF); these manifestations are largely age/immune
status dependent2). Undifferentiated fever: infants and children infected with dengue virus for
the first time (i.e. primary dengue infection) usually develop a simple fever, sometimes with a
rash.
Dengue fever is most common in adults and older children; it is an acute biphasic
febrile illness with headache, myalgia, arthralgia, rash and leucopenia. Although DF is com-
monly benign, it may be an incapacitating disease with severe muscle and joint pain
(``Breakbone fever '), particularly in adults and very occasionally severe haemorrhage occurs.
Infection with one dengue serotype gives partial protection against the others thus DF
seldom occurs among indigenous people in dengue endemic areas.
Dengue haemorrhagic fever is most common in children less than 15 years of age and
causes a significant number of deaths; acute fever is associated with haemorrhagic diatheses
and a tendency to develop fatal shock (dengue shock syndrome). Abnormal haemostasis and
plasma leakage are the main pathophysiologic changes and thrombocytopenia with concurrent
haemoconcentration are constant findings3*.
DHF occurs most commonly in children who have experienced a previous primary
dengue infection; the reason for this is not well understood. Epidemiological evidences sug-
gest that the sequences of the infecting dengue serotypes and the interval between the two
infections (i.e. primary and secondary) may be important factors contributing to the occur-




After an incubation period of 4-6 days from the time of the mosquito bite, various
non-specific undifferentiated prodomes, such as headache, backache, general malaise may
develop. Typically, however, the onset of DF in adults is sudden with a sharp rise in
temperature occasionally with chilliness associated with severe headache and flushed or mottl-
ed facial skin. Within 24 hours, the following symptoms may develop:
- retro-orbital pain, particularly on eye movement or eye pressure, photophobia
- backache, pain in the muscles and joints of the extremities.
Other common symptoms include:
- anorexia, altered taste sensation
- constipation
- colicky pain and abdominal tenderness
- dragging pains in the inguinal region
-　sore throat
- general depression
Symptoms vary in severity and usually persist for several days.
Fever: the temperature is usually between 39℃ and 40℃ , and the fever lasts approximately
5-7 days. Occasionally a biphasic fever is observed.
Rash: diffuse flushing, mottling or fleeting pinpoint eruptions may be observed on the face,
neck and chest during the first half of the febrile period, and a conspicuous rash, that may
be maculopapular or scarlatiniform, appears on approximately the third or fourth day. This
rash starts on the chest and trunk and spreads to the extremities and face, and may be ac-
companied by itching and dermal hyperaesthesia. There may be generalized enlargement of
the lymph nodes, but the liver and spleen are not usually enlarged.
Towards the end of the febrile period or immediately after defevrescence, the generaliz-
ed rash fades and localized clusters of petechiae may appear over the dorsum of the feet, on
the legs, hands and arms. This confluent petechial rash is characterized by scattered pale
round areas of normal skin.
Course: the relative duration or severity of DF varies between individuals in a given
epidemic, as well as from one epidemic to another.
Convalencence may be abrupt and uneventful but is often prolonged particularly in adults,
sometimes taking several weeks, and may be accompanied by pronounced asthenia and
depression. Bradycardia is common during this peroid. Haemorrhagic complication, such as
epistaxis, gingival bleeding, gastrointestinal bleeding, haematuria, and hyper - menorrhoea, ac-
company many epidemics of DF, and on rare occasions severe bleeding has caused deaths in
some epidemics2'. DF complicated by haemorrhage must be differentiated from DHF.
Investigation: Laboratory findings during the acute illness are as follows:
Total WBC is usually normal at the onset of fever, but then leucopenia develops and
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lasts throughout the febrile period. Initially, there is a progressive shift of neutrophils to the
left- that is an increased proportion of immature non-segmented nuclear forms which per-
sist into convalescence, there is marked depletion of circulating lymphocytes.
Platelet counts are usually normal, as are other components of the blood clotting
mechanisms. Infrequently thrombocytopenia may be observed.
Serum biochemistry and enzymes are normal.
Diagnosis
Differential diagnosis of DF includes a wide variety of viral (including chikungunya),
bacterial and rickettsial infections that produce a similar syndrome. It is impossible to
diagnose mild dengue infection clinically, particularly in sporadic cases. A definite diagnosis
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is confirmed by virus isolation and/or serology.
Managemen t
The management of DF is symptomatic and supportive.
- Bed rest is advisable during the acute febrile phase.
Antipyretics or sponging are required to keep body temperature below 39℃.
- Analgesics or a mild sedative may be required for those with severe pain.
-　Oral fluid and electrolyte therapy is recommended for patients with excessive
sweating, nausea, vomiting or dia汀hoea
ln areas where DHF is endemic, patients with dengue syndrome should be monitored




The pathogenetic mechanism of DHF is not clear, but two main pathophysiologic
changes occurs2':
-　Vascular permeability increases that results in plasma leakage, leading to
hypovolaemta and shock.
- Abnormal haemostasis, due to vasculopathy, thrombocytopenia and coagulopathy,
leading to various hemorrhagic manifestations.
A constant finding in DHF is activation of the complement system with profound
depression of C3 and C5 levels. Immune complexes have been described in DHF assoicated
with secondary dengue virus infection and it is postulated that these may contribute to com-
plement activation and release of C3a and C5a, suspected to be permeability increasing
mediators.
The severity of DHF compared with DF may be explained by the enchancement of
virus multiplication in macrophages by heterotypic antibodies resulting from a previous
dengue infection. There are evidences suggesting that cell mediated immune response may
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also be involved in the pathogenesis of DHF.
Clinical features
Typically, DHF begins abruptly with high fever accompanied by facial flushing and
headache. Anorexia, vomiting and abdominal pain are common. During the first few days,
the illness resembles classical DF, but a maculopapular rash is less common.
A haemorrhagic diathesis is commonly demonstrated by scattered fine petechiae on the
extremities, face and trunk, and in the axillae. A postive tourniquet test and a tendency to
bruise at venipuncture sites are always present. Bleeding from the nose, gums and
gastrointestinal tract are less common. Haematuna is extremely rare.
The liver is usually enlarged, soft and tender. Approximately 50% of patients have
generalized lymphadenopathy.
The critical stage is reached after 2-7 days, when the fever subsides. Accompanying
or shortly after a rapid drop in body temperature, varying degrees of circulatory disturbance
occurs. The child is commonly restless and has cold extremities and sometimes sweats.
In less severe cases, the changes in vital signs are minimal and transient. The patient
recovers spontaneously or after a brief period of therapy.
In more severe cases, shock ensues and the patient may die within 12-24 hours. Pro-
longed shock is often complicated by metabolic acidosis and severe bleeding, which indicate
a poor prognosis. If the patient is appropriately treated before irreversible shock has
developed, rapid recovery is the rule.
Encephalitic signs associated with intracranial haemorrhage, metabolic and electrolyte
disturbances, and hepatic failure (a form of Reye s syndrome) may occur. They are uncom-
mon but carry a grave prognosis.
Course: Convalescence is commonly short and uneventful, and is often accompanied by sinus
bradycardia and characteristic con fluent petechial rash with scattered round areas of pale
skin as described in DF. The duration of DHF is about 7-10 days in most cases.
Laboratory Investigations
Laboratory findings in DHF are as follows:
A normal WBC or leucopenia is common initially with neutrophils p町edominating.
Towards the end of the febrile phase, a relative lymphocytosis with more than 15% atypical
lymphocytes is common.
Thrombocytopenia (≦ 100,000/cumm.) and hemoconcentration (≧20% increase) are con-
stant findings. The platelet count drops shortly before, or at the same time, as the
haematocrit increases: both changes occur before the subsidence of fever and before onset of
shock.
Chest X-ray: right pleural effusion or bilateral pleural effusion, is commonly found at
the peak of plasma leakage.
Liver function test: 80% of DHF patients have slight elevation of AST/ALT (not more
than lOOU) and AST level is about 2-3 times of ALT. Hypoalbummemia and reverse
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albumin to globulin ratio are frequently observed.
Coagulogram: most cases have slightly prolonged partial thromboplastin time (PTT)
and thrombm time (TT). Prothrombin time (PT) is prolonged in about one third of cases.
Pointers to the diagnosis of dengue haemorrhagic fever
- High fever of acute onset, usually in a child
- Petecmal haemorrhages and/or a positive tourniquet test o洗en within 24-48 hours
of onset
- Tender hepatomegaly
- Normal WBC or leucopenia
- A fall in platelets preceding or simultaneous with a rise in haematocrit (Note: this is an
important feature, helping to distinguish DHF from DF and other viral infections)
- Pleura! effusion (usually on the right side)
-　Shock
Differential diagnosis of DHF during the acute febrile phase are many tropical infections in-
eluding leptospirosis and malaria. With the presence of characteristic manifestations, the
clinical diagnosis is confirmed in almost 95% of cases. A rising haematocrit and selective
leakage of plasma into pleural and abdominal cavities appear to be unique to DHF. When all
the clinical criteria are accompanied by shock, the diagnosis of DHF is definite. The
presence of a pleural effusion, commonly on the right side, supports a diagnosis of DHF in
cases in which haemoconcentration may be absent due to au untimely test or early fluid
replacement, and in cases when severe bleeding has occurred. A normal ESR in DHF/DSS
help to differentiate this disease from bacterial infection and septic shock5).
Laboratory Diagnosis2'
Clinical diagnosis can be confirmed by serological testing and virus isolation from the
blood during the early febrile phase. Antibody to all dengue virus antigens increases rapidly
in patients with secondary dengue infection. A diagnostic (four fold) increases in dengue
virus haemagglutination inhibition (HI) antibody can usually be demonstrated from sera ob-
tamed early in the febrile phase on admission, and also 3-5 days later in most DHF cases.
A third specimen 2-3 weeks after onset is requried to confirm laboratory diagnosis of
primary infection, particularly in infants under 1 year of age7).
At present, ELISA for lgM and lgG specific dengue antibody has the advantage over
HI test in that acute dengue infection could be definitely diagnosed from only acute blood
specimen with a sensitivity of 78%. With paired sera (only 2-3 days apart), the sensitivity of
the test increases to 97%. The definite diagnosis for acute dengue inection by this method is
a detection of more than 40 units of lgM specific dengue antibody. In addtion, ELISA techni-
que can differentiate primary from secondary dengue infection and also dengue infection
from Japanese encephalitis6).
Managemen t2'3'7>
The management of DHF during the febrile phase is similar to that of DF. Antipyretics
may be indicated but salicylates should be avoided. It should be noted that antipyretics can
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not reduce the duration of fever in DHF. Paracetamol is recommended and should be used
only to keep the temperature below 39℃. Prognosis of DHF depends on early recognition of
plasma leakage which can be achieved by frequent monitoring of patients for a drop in
platelet counts and a rise in hematocnt level. The critical period is at the time of
defevrescence which occurs approximately on or after the third day of illness. A drop in the
platelet count to < 100,000/cumm or less than 1 -2 platelets/oil field (average of 10 oild field
counts) usually precedes a rise in hematocnt and the time of defevrescence. A rise in
hematocrit of 20% or more (e. g increase from 35% to 42%) reflects a significant plasma loss
and indicates a need for intravenous fluid therapy. Early volume replacement of plasma
losses with isotonic salt solution can modify disease severity and prevent shock.
In mild to moderate cases (grade I and H)2) intravenous fluid therapy may be given
for a period of 12-24 hours at an outpatient clinic. Patients who continue to have high
hematocrit, platelet counts below 50,000/皿　or present with any type of spontaneous hemor-
rhage other than petechiae should be hospitalized.
The volume and type of intravenous fluids should be similar to that used in the treat-
ment of dia汀heal disease with mild to moderate isotonic dehydration (five to eight percent
deficit). The required volume should be charted on a two to three hourly basis and the rate
of infusion should be carefully balanced throughout the 24-48 hour peroid of leakage. Serial
hematocrit determination every 4-6 hours, frequent record of vital signs and urine output
are essential in monitoring the rate of intravenous infusion in order to assure an adequate
volume replacement and to avoid over transfusion.
Management of shock
Dengue shock syndrome (DSS) is a medical emergency that requires prompt and
vigorous volume replacement therapy for the rapid and massive plasma losses. There are
also electrolyte and acid base disturbances. It must be considered that in DHF there are
marked thrombocytopenia, abnormal platelet function, and potential for disseminated in-
travascular clotting to develop. These abnormal hemostasis are ready factors to cause severe
bleeding particularly in cases with prolonged shock.
Treatment of DSS (grade 1 and F)
The following regimen has been used at the Children s Hospital for the past three
decades and has been recommended by WHO2) since 1974.
1. Replacement of plasma losses.
Immediate volume replacement with isotonic salt solution (5% D in Rmger lactate or
Ringer acetate solution or 5% D in normal saline solution) at the rate of 10-20ml/kg/hr or in
the case of profound shock (grade N) as a bolus of lOml/kg (one to two times). A rapid infu-
sion is continued until improvement is apparent then reduce the rate and adjust thereafter ac-
cording to the rate of plasma leakage as guided by hematocrit levels.
In case no definite improvement and hematocnt remains high, colloidal e.g. Dextran
40, plasma or the plasma substitute should be given following the initial瓜uid at a rate of
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10-20ml/kg/hr. Blood transfusion is indicated in cases with refractory shock with declining
hematocrit value after initial fluid replacement.
2. Continue replacement for furthur plasma losses for the period of 24-48 hours. In-
travenous fluid should be discontinued at the time around 24- 48 hours after defevrescence,
when hematocnt declines and becomes stable (approximately 40%), with good vital signs and
good urine output.
3. Correction of electrolyte and metabolic disturbances. Hyponatremia and metabolic
acidosis are common in severe cases. Electrolyes and blood gases should be determined
periodically in severe cases and appropriately corrected as indicated.
4. Blood trans血sion. Severe bleeding mostly from gastrointestinal tract that required
blood trans山sion was observed in about 15% of shock cases2). A refractory shock despite
declminmg hematocrit level (e.g. from 50% to 40%) after adequeate volume replacement with
crystolloid and/or colloid indicates significant bleeding that requires blood transfusuion. Fresh
whole blood (FWB) is preferable and should be given only in such a volume that is needed to
restore red cell mass to normal.
5. Unusual manifestations/complications8'.
The most frequently encountered are acute hepatic failure and renal failure (which
usually follow a complicated case with prolonged shock) that required specific and ap-
propnate treatment. Early blood exchange transfusion in case of hepatic encephalopathy or
Reye s like syndrome has proved to be life saving in a number of cases, as is hemodialysis in
renal failure.
Some DHF patients present unusual manifestations with signs and symptoms of CNS
involvement, as convulsion and/or comatose. This has been shown to be encephalopathy not
encephalitis which may be a terminal stage of DHF cases with intracranial hemo血age or oc-
culsion associated with DIG. Electrolyte and metabolic disturbances are found to be
associated factors of encephalopathy. The most commonly found is encephalopathy
associated with hepatic failure which is a major contributing cause of death in DHF now.
The experience at the Children's Hospital where a great number of DHF cases were
seen each year, the treatment with this regimen, without using corticosteroid or any
vasopressure drugs, has resulted in a steady decline in mortality of shock cases. The case
fatality rate drops from about lO% in 1970 to 2% in 1984 and 0.2% in 1990 (Fig. 1.). Results
of the studies from various places on the use of corticosteroid in treating DSS showed no
benefit either in fatality rate or a reduction in volume of fluid therapy or duration of therapy
9). The prognosis of DHF, a disease of potential fatal shock, thus depends on early diagnosis
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Fig. 1. Hospitalized cases of dengue hemorrhagis fever,
children's Hospital, Bangkok, Thailand
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